LinkedInXFacebook
Subscribe
Orthopedics This Week
  • Opinions
  • |My Feed
  • |Events
  • |Company Directory
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Foot & Ankle/Forma Medical Receives U.S. Patent Covering Minimally Invasive Plate Arthrodesis (MIPA™) Methods Across the Foot
Foot & Ankle

Forma Medical Receives U.S. Patent Covering Minimally Invasive Plate Arthrodesis (MIPA™) Methods Across the Foot

October 21, 2026 2 min read Premium comments

Advertisement

Forma Medical Receives U.S. Patent Covering Minimally Invasive Plate Arthrodesis (MIPA™) Methods Across the Foot
Courtesy of Forma Medical, Inc.
patentForma Medical IncarthrodesisMIPAminimally invasive plate arthrodesis

CAMP HILL, Pa.--(BUSINESS WIRE)--Forma Medical Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,751,749, titled “System for Joint Fixation of Extremity Bone and Related Methods.” The patent, which issued October 6, 2026, covers surgical methods for what Forma calls minimally invasive plate arthrodesis, or MIPA™, in which a plate is introduced and secured across a joint of the foot through small incisions rather than a traditional open exposure.

Fusion surgery, or arthrodesis, permanently joins two bones across a joint damaged by arthritis or deformity. It is a mainstay of foot and ankle reconstruction at the big toe, the midfoot, and the hindfoot. Surgeons have long faced a trade-off in how they perform it. Plates provide stable, well-established fixation but have traditionally required a longer incision to implant. Minimally invasive techniques shrink the incision but have typically relied on a screw-only construct. MIPA is designed to remove that trade-off.

The name echoes a shift in fracture care. Since the 1990s, orthopedic trauma surgeons have adopted minimally invasive plate osteosynthesis (MIPO), sliding fracture plates beneath the skin through small incisions to protect the surrounding soft tissue and blood supply. MIPA applies the same principles to joint fusion.

“The fixation surgeons trust, through the small incisions patients ask for. That is what surgeons told us they needed, and MIPA is designed to deliver both,” said Andrew C. Davison, CEO of Forma Medical. “This patent covers the method, not a single implant. The big toe was our starting point, with more than 1,000 procedures to date. The claims extend to other joints of the foot where surgeons already reach for a plate.”

“In urgent fracture care, we have evolved to less invasive surgical approaches for internal fixation, with less anatomic distortion and soft tissue dissection,” said Jesse F. Doty, MD, FAAOS, a fellowship-trained orthopedic foot and ankle surgeon at Integrity Orthopedics and Professor of Orthopaedic Surgery at the University of Tennessee and a co-inventor of the patented technology. “Elective fusion has been slower to progress to an established equivalent until now. MIPA offers a defined, repeatable way to deliver more robust plate fixation through smaller incisions, providing the same benefits we've seen from minimally invasive surgery in other anatomic areas, but without compromised stability. I’ve used MIPA for MTP joint fusions in my own practice for years now. My experience and patient feedback have been highly encouraging, and I plan to submit my clinical outcomes for publication later this year.”

About Forma Medical
Forma Medical Inc. is a privately held orthopedic device company focused on developing differentiated solutions that combine strong biomechanical principles with minimally invasive surgical techniques. The company’s flagship OptimalMTP® system is designed to advance the standard of care in first MTP joint fusion by delivering stability, reproducibility, and efficiency through an MIS approach. OptimalMTP received FDA 510(k) clearance in 2024 and has been used in more than 1,000 procedures.

Contacts

James A. Gault
Forma Medical
support@formamedical.com

Author

TH
TJ Halvorson

The De Angelis Group | Orthopedics This Week | MSK Innovations

Why This Matters

Two Perspectives

MBA Lens: Economic and industry impact

Forma Medical's new patent for Minimally Invasive Plate Arthrodesis (MIPA™) methods across the foot represents a strategic move to capture market share in foot and ankle reconstruction. By combining stable plate fixation with smaller incisions, MIPA addresses a critical trade-off, potentially driving broader adoption. This approach aims to meet both surgeon preference for robust fixation and patient demand for less invasive procedures, enhancing market competitiveness.

  • The patent covers surgical methods, not a single implant, allowing broad application across various foot joints.
  • Forma's OptimalMTP® system, utilizing MIPA for first MTP joint fusion, has already been used in over 1,000 procedures.

PhD Lens: Clinical and outcomes impact

The newly issued patent for Minimally Invasive Plate Arthrodesis (MIPA™) details surgical methods for joint fixation using plates introduced through small incisions. This technique mirrors principles from minimally invasive plate osteosynthesis (MIPO) in fracture care, aiming to provide robust fixation while minimizing soft tissue disruption. Clinical experience with MIPA for MTP joint fusions has been encouraging, with outcomes slated for future publication.

  • MIPA's mechanism involves sliding plates beneath the skin to protect surrounding soft tissue and blood supply during joint fusion.
  • Initial clinical use by a co-inventor for MTP joint fusions shows positive patient feedback, with formal publication of outcomes pending.
React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

Orthopedics This Week’s mission is to connect the orthopedic community with the people, ideas, and innovations shaping the future of musculoskeletal care.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Opinions
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, opinions, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy